



AN RIALTÓIR CÓGAISÍOCHTA  
THE PHARMACY REGULATOR

**The Pharmaceutical Society of Ireland 2017 Annual Report  
on Protected Disclosures**

## Report on the Protected Disclosures Act 2014

The Protected Disclosures Act 2014 commenced on 15 July 2014. It provides for the protection of persons from action being taken against them in respect of disclosures made by them in the public interest.

This report covers the period from 1 January 2017 to 31 December 2017. The purpose of this report is to discharge the statutory obligation of the PSI under Section 22 of the Protected Disclosures Act 2014 (“the Act”) to prepare and publish not later than 30 June in each year a report detailing:

- (a) the number of protected disclosures made to the PSI,
- (b) the action (if any) taken in response to those protected disclosures, and
- (c) such other information relating to those protected disclosures and the action taken as may be requested by the Minister from time to time (No such information was requested by the Minister).

### Section 6

- No disclosures were made in the timeframe set out above to the PSI as an employer, under Section 6 of the Act.

### Section 7

- Pursuant to Statutory Instrument No. 339 of 2014, the Registrar of the PSI has been prescribed as the prescribed person in respect of all matters relating to the regulation of pharmacists and pharmacies in the State, including the Society’s responsibility for supervising compliance with the Pharmacy Act 2007.
- In 2017, 19 potential protected disclosures were received from workers<sup>1</sup> by the PSI under Section 7 of the Act. The information disclosed in each case was reviewed and dealt with in accordance with standard PSI policy and procedures. The PSI did not disclose the identity of these workers.



---

**Mr Rory O'Donnell**  
**President**

22 March 2018

<sup>1</sup> As set out in the definition of “worker” contained at section 3(1) of the Act